Apollo Therapeutics Secures $226.5M in Series C Funding

Boston, MA, September 6, 2023 (Business Wire) -- In a significant milestone, Apollo Therapeutics, a forward-looking biopharmaceutical firm dedicated to translating cutting-edge medical research into therapeutic breakthroughs via its innovative hub-and-spoke model, has just closed a $226.5 million Series C financing round. This funding initiative is led by Patient Square Capital.

Read full article here.